Loading clinical trials...
Loading clinical trials...
The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma)
Conditions
Interventions
pemetrexed/cisplatin intercalating gefitinib
pemetrexed/cisplatin
Locations
1
China
The first affiliated hospital of Guangzhou MC
Guangzhou, Guangdong, China
Start Date
December 1, 2016
Primary Completion Date
December 30, 2019
Completion Date
December 30, 2021
Last Updated
March 28, 2019
NCT07485114
NCT06066138
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Guangzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions